Kari Wilder-Romans

3.3k total citations · 1 hit paper
38 papers, 1.7k citations indexed

About

Kari Wilder-Romans is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kari Wilder-Romans has authored 38 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 21 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kari Wilder-Romans's work include Prostate Cancer Treatment and Research (10 papers), PARP inhibition in cancer therapy (10 papers) and Estrogen and related hormone effects (8 papers). Kari Wilder-Romans is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), PARP inhibition in cancer therapy (10 papers) and Estrogen and related hormone effects (8 papers). Kari Wilder-Romans collaborates with scholars based in United States, Slovakia and Finland. Kari Wilder-Romans's co-authors include Felix Y. Feng, Arul M. Chinnaiyan, Shaomeng Wang, Irfan A. Asangani, Vijaya L. Dommeti, June Escara‐Wilke, Xuhong Cao, Carl G. Engelke, Zhaohui Qin and Corey Speers and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Kari Wilder-Romans

36 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

2014 737 citations Irfan A. Asangani, Vijaya L. Dommeti et al. Nature profile →

Peers

Countries citing papers authored by Kari Wilder-Romans

Since Specialization

Citations

This map shows the geographic impact of Kari Wilder-Romans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari Wilder-Romans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari Wilder-Romans more than expected).

Fields of papers citing papers by Kari Wilder-Romans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kari Wilder-Romans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari Wilder-Romans. The network helps show where Kari Wilder-Romans may publish in the future.

Co-authorship network of co-authors of Kari Wilder-Romans

This figure shows the co-authorship network connecting the top 25 collaborators of Kari Wilder-Romans. A scholar is included among the top collaborators of Kari Wilder-Romans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kari Wilder-Romans. Kari Wilder-Romans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer 2022 ·British Journal of Cancer ·Anna R. Michmerhuizen, (unknown), (unknown), (unknown), (unknown), Rachel Schwartz, Kari Wilder-Romans, Joel R. Eisner, James M. Rae, Lori J. Pierce, Corey Speers	4
2	Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression 2022 ·Cancer Research Communications ·(unknown), Benjamin C. Chandler, Anna R. Michmerhuizen, (unknown), (unknown), Kari Wilder-Romans, Meilan Liu, (unknown), (unknown), (unknown), (unknown), Lori J. Pierce, James M. Rae, Corey Speers	7
3	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models 2022 ·npj Breast Cancer ·Anna R. Michmerhuizen, (unknown), (unknown), (unknown), Rachel Schwartz, Kari Wilder-Romans, Meilan Liu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bryan L. Wharram, Daniel F. Hayes, James M. Rae, Lori J. Pierce, Corey Speers	14
4	RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes 2021 ·JCI Insight ·(unknown), (unknown), Anna R. Michmerhuizen, (unknown), Kari Wilder-Romans, Benjamin C. Chandler, Meilan Liu, (unknown), (unknown), (unknown), Erin F. Cobain, Theodore S. Lawrence, Lori J. Pierce, James M. Rae, Corey Speers	21
5	Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers 2020 ·Clinical Cancer Research ·(unknown), (unknown), Benjamin C. Chandler, Anna R. Michmerhuizen, (unknown), (unknown), Kari Wilder-Romans, Meilan Liu, Christina L. Gersch, José M. Larios, Lori J. Pierce, James M. Rae, Corey Speers	35
6	Neddylation inactivation represses androgen receptor transcription and inhibits growth, survival and invasion of prostate cancer cells 2020 ·Neoplasia ·Xiaochen Zhou, Sumin Han, Kari Wilder-Romans, Grace Y. Sun, Hong‐Jian Zhu, Xiaoqiang Liu, Mingjia Tan, Gongxian Wang, Felix Y. Feng, Yi Sun	18
7	A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Corey Speers, S. Laura Chang, (unknown), (unknown), Eric Olsen, Ben Chandler, (unknown), Meilan Liu, Meleah Cameron, Anna R. Michmerhuizen, Kari Wilder-Romans, Shuang G. Zhao, Shyam Nyati, Harry Bartelink, Felix Y. Feng, Lori J. Pierce	12
8	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer 2019 ·Clinical Cancer Research ·Steven Kregel, Rohit Malik, Irfan A. Asangani, Kari Wilder-Romans, Thekkelnaycke M. Rajendiran, Lanbo Xiao, Josh N. Vo, Tanu Soni, Marcin Cieślik, (unknown), Bing Zhou, Xuhong Cao, Corey Speers, Shaomeng Wang, Arul M. Chinnaiyan	26
9	Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53 -Deficient Cancers 2019 ·Molecular Cancer Research ·Moloy T. Goswami, (unknown), Sumin Han, (unknown), (unknown), (unknown), (unknown), (unknown), Kari Wilder-Romans, Daniel R. Rhodes, Felix Y. Feng, Scott A. Tomlins	9
10	PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation 2019 ·Molecular Cancer Therapeutics ·Anna R. Michmerhuizen, (unknown), (unknown), Benjamin C. Chandler, Kari Wilder-Romans, Meleah Cameron, Eric Olsen, Dafydd G. Thomas, (unknown), (unknown), (unknown), Meilan Liu, Shyam Nyati, Lori J. Pierce, Reshma Jagsi, Corey Speers	41
11	EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins 2018 ·Cancer Research ·Paradesi Naidu Gollavilli, (unknown), Kari Wilder-Romans, Ramakrishnan Natesan, Carl G. Engelke, Vijaya L. Dommeti, Pranathi M. Krishnamurthy, (unknown), Ingrid J. Apel, Tianlei Xu, Zhaohui Qin, Felix Y. Feng, Irfan A. Asangani	52
12	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer 2017 ·npj Breast Cancer ·Corey Speers, Shuang G. Zhao, Benjamin C. Chandler, Meilan Liu, Kari Wilder-Romans, Eric Olsen, Shyam Nyati, (unknown), Prasanna Alluri, Vishal Kothari, Daniel F. Hayes, Theodore S. Lawrence, Daniel E. Spratt, Daniel Wahl, Lori J. Pierce, Felix Y. Feng	49
13	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis 2016 ·Cancer Research ·Daniel Wahl, Joseph Dresser, Kari Wilder-Romans, Joshua D. Parsels, Shuang G. Zhao, Mary A. Davis, Lili Zhao, Maureen Kachman, Stefanie Wernisch, Charles Burant, Meredith A. Morgan, Felix Y. Feng, Corey Speers, Costas A. Lyssiotis, Theodore S. Lawrence	67
14	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer 2016 ·Molecular Cancer Research ·Irfan A. Asangani, Kari Wilder-Romans, Vijaya L. Dommeti, Pranathi M. Krishnamurthy, Ingrid J. Apel, June Escara‐Wilke, Stephen R. Plymate, Nora M. Navone, Shaomeng Wang, Felix Y. Feng, Arul M. Chinnaiyan	127
15	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer 2016 ·Neoplasia ·Yuanyuan Qiao, Felix Y. Feng, Yugang Wang, Xuhong Cao, Sumin Han, Kari Wilder-Romans, Nora M. Navone, Christopher J. Logothetis, Russell S. Taichman, Evan T. Keller, Ganesh S. Palapattu, Ajjai Alva, David C. Smith, Scott A. Tomlins, Arul M. Chinnaiyan, Todd M. Morgan	18
16	Development and Validation of a Novel Platform-Independent Metastasis Signature in Human Breast Cancer 2015 ·PLoS ONE ·Shuang G. Zhao, Mark Shilkrut, Corey Speers, Meilan Liu, Kari Wilder-Romans, Theodore S. Lawrence, Lori J. Pierce, Felix Y. Feng	10
17	Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer 2014 ·Breast Cancer Research and Treatment ·Felix Y. Feng, Corey Speers, Meilan Liu, Will Jackson, Dominic H. Moon, Jacob Rinkinen, Kari Wilder-Romans, Reshma Jagsi, Lori J. Pierce	33
18	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer breakdown → 2014 ·Nature ·Irfan A. Asangani, Vijaya L. Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieślik, Rendong Yang, June Escara‐Wilke, Kari Wilder-Romans, (unknown), Carl G. Engelke, (unknown), Xiaojun Jing, Yi-Mi Wu, Xuhong Cao, Zhaohui Qin, Shaomeng Wang, Felix Y. Feng, Arul M. Chinnaiyan	737
19	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes 2012 ·Journal of Clinical Investigation ·Michael A. Augello, Craig J. Burd, Ruth Birbe, Christopher McNair, Adam Ertel, Michael S. Magee, Daniel E. Frigo, Kari Wilder-Romans, Mark Shilkrut, Sumin Han, Danielle L. Jernigan, Jeffry L. Dean, Alessandro Fatatis, Donald P. McDonnell, Tapio Visakorpi, Felix Y. Feng, Karen E. Knudsen	35
20	Enzastaurin, an inhibitor of PKCβ, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells 2008 ·Translational Oncology ·Aaron C. Spalding, Benjamin D. Zeitlin, Kari Wilder-Romans, Mary E. Davis, Jacques E. Nör, Theodore S. Lawrence, Edgar Ben‐Josef	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact